Search results for "Severity"

showing 10 items of 1287 documents

Adalimumab Induction for Crohn’s Disease

2006

DrugCrohn's diseasemedicine.medical_specialtyHepatologybiologybusiness.industrymedia_common.quotation_subjectGastroenterologyMEDLINEmedicine.diseaseInternal medicineSeverity of illnessMonoclonalbiology.proteinAdalimumabMedicineAntibodybusinessRisk assessmentmedia_commonmedicine.drugGastroenterology
researchProduct

Cerebellar magnetic stimulation decreases levodopa-induced dyskinesias in Parkinson disease

2009

BACKGROUND: The neural mechanisms and the circuitry involved in levodopa-induced dyskinesia (LID) are still partially obscure. LID can be considered the consequence of an abnormal pattern or code of activity that originates and is conveyed from the basal ganglia to the thalamus and the cortical motor areas. However, not only striatothalamocortical motor circuits but also other interconnected pathways could be implicated in its pathogenesis. METHODS: In a series of experiments, we applied repetitive transcranial magnetic stimulation (rTMS) over the lateral cerebellum in a group of patients with advanced Parkinson disease, to investigate whether modulation of cerebellothalamocortical circuits…

Dyskinesia Drug-InducedLevodopaCerebellummedicine.medical_treatmentCTBStmSeverity of Illness IndexrehabilitationNOLevodopaNeural PathwaySeverity of Illness Index; Analysis of Variance; Levodopa; Dyskinesia Drug-Induced; Humans; Cerebellum; Aged; Neural Inhibition; Thalamus; Motor Cortex; Parkinson Disease; Evoked Potentials Motor; Neural Pathways; Middle Aged; Neuronal Plasticity; Transcranial Magnetic StimulationThalamusCerebellumNeural PathwaysBasal gangliamedicineHumansEvoked PotentialsThalamuAgedAnalysis of VarianceNeuronal PlasticityDyskinesiaMotor CortexNeural InhibitionParkinson DiseaseMiddle AgedEvoked Potentials MotorTranscranial Magnetic StimulationAged; Analysis of Variance; Cerebellum; Drug-Induced Dyskinesia; Evoked Potentials; Motor; Humans; Levodopa; Middle Aged; Motor Cortex; Neural Inhibition; Neural Pathways; Neuronal Plasticity; Parkinson Disease; Severity of Illness Index; Thalamus; Transcranial Magnetic StimulationTranscranial magnetic stimulationmedicine.anatomical_structureMotorDyskinesiaDrug-Inducedparkinson's diseaseSettore MED/26 - NeurologiaDrug-Induced DyskinesiaNeurology (clinical)Primary motor cortexmedicine.symptomPsychologyNeuroscienceHumanMotor cortexmedicine.drugNeurology
researchProduct

Both Short- and Long-Acting D-1/D-2 Dopamine Agonists Induce Less Dyskinesia than l-DOPA in the MPTP-Lesioned Common Marmoset (Callithrix jacchus)

2002

Abstract The current concept of dyskinesia is that pulsatile stimulation of D-1 or D-2 receptors by l -DOPA or short-acting dopamine agonists is more likely to induce dyskinesia compared to long-acting drugs producing more continuous receptor stimulation. We now investigate the ability of two mixed D-1/D-2 agonists, namely pergolide (long-acting) and apomorphine (short-acting), to induce dyskinesia in drug-naive MPTP-lesioned primates, compared to l -DOPA. Adult common marmosets ( Callithrix jacchus ) were lesioned with MPTP (2 mg/kg/day sc for 5 days) and subsequently treated with equieffective antiparkinsonian doses of l -DOPA, apomorphine, or pergolide for 28 days. l -DOPA, apomorphine, …

Dyskinesia Drug-Inducedmedicine.medical_specialtyParkinson's diseaseL-DOPApergolideMotor ActivityapomorphineSeverity of Illness IndexDopamine agonistAntiparkinson AgentsLevodopaParkinson’s disease.Disability Evaluationchemistry.chemical_compoundParkinsonian DisordersDevelopmental NeuroscienceDopamineInternal medicineAnimalsMedicineMPTPPergolidemarmosetBehavior AnimalReceptors Dopamine D2business.industryReceptors Dopamine D1MPTPCallithrixmedicine.diseasenervous system diseasesApomorphineDisease Models AnimaldyskinesiaEndocrinologyNeurologychemistryDyskinesia1-Methyl-4-phenyl-1236-tetrahydropyridineDopamine receptorDopamine AgonistsSettore BIO/14 - Farmacologiamedicine.symptombusinessmedicine.drugExperimental Neurology
researchProduct

Determinants of COVID-19 Vaccine Rollouts and Their Effects on Health Outcomes

2022

Background Vaccination against the coronavirus disease (SARS-CoV-2) is understood to be the key way out of the COVID-19 pandemic. Limited evidence exists on the determinants of vaccine rollouts and their health effects at the country level. Objective Examine the determinants of COVID-19 vaccine rollouts and their effects on health outcomes. Methods Ordinary least squares regressions with standard errors clustered at the country level for Cross-section and Panel daily data of vaccinations and various health outcomes (new COVID-19 cases, fatalities, intensive care unit (ICU) admissions) for an unbalanced sample of about 200 countries during the period 16 December 2020 to 20 June 2021. Results…

Economics and Econometricsand (iii) COVID-19 cases in neighboring countries can lead to an increase in a country's domestic caseload and hamper efforts in taming its own local outbreak. Conclusions: By providing an early broad overview of the quantitative empirical estimates of the determinants of vaccine rollouts and the effects of COVID-19 vaccines our paper can help policymakers make informed decisions about local and global distributions of vaccines as well as related policy tools such as containment measure.Coronavirus disease 2019 (COVID-19)business.industryHealth PolicyNational accountsOutbreakGeneral Medicine(ii) vaccine deployment significantly reduces new COVID-19 infections Intensive Care Unit (ICU) admissions and fatalities and is more effective when coupled with stringent containment measures or when a country is experiencing a large outbreakVaccination against the coronavirus disease (SARS-CoV-2) is understood to be the key way out of the COVID-19 pandemic. Limited evidence exists on the determinants of vaccine rollouts and their health effects at the country level. Objective: Examine the determinants of COVID-19 vaccine rollouts and their effects on health outcomes. Methods: Ordinary least squares regressions with standard errors clustered at the country level for Cross-section and Panel daily data of vaccinations and various health outcomes (new COVID-19 cases fatalities intensive care unit (ICU) admissions) for an unbalanced sample of about 200 countries during the period 16 December 2020 to 20 June 2021. Results: We find evidence that: (i) early vaccine procurement domestic production of vaccines the severity of the pandemic a country's health infrastructure and vaccine acceptance are significant determinants of the speed of vaccination rolloutHealth outcomesIntensive care unitlaw.inventionVaccinationProcurementlawEnvironmental healthPandemicGeneral Earth and Planetary SciencesMedicinebusinessGeneral Environmental ScienceIMF Working Papers
researchProduct

Should mild hypogammaglobulinemia be managed as severe hypogammaglobulinemia? A study of 389 patients with secondary hypogammaglobulinemia.

2014

Although secondary hypogammaglobulinemia is more frequent than primary hypogammaglobulinemia, its etiology and management are poorly described, particularly for mild hypogammaglobulinemia.This retrospective observational study included all adult patients with a gammaglobulin level6.4g/L on serum electrophoresis identified at Dijon teaching hospital between April and September 2012. Clinico-biological features, etiologies and infectious complications were collected at inclusion and compared between group 1 (gammaglobulin5g/L, severe hypogammaglobulinemia), and group 2 (gammaglobulin6.4 and ≥5g/L, mild hypogammaglobulinemia).Among the 4011 serum electrophoreses, 570 samples from 389 patients …

ElectrophoresisMalePediatricsmedicine.medical_specialtyInfectionsSeverity of Illness IndexHypogammaglobulinemiaPneumococcal Vaccinesimmune system diseasesAgammaglobulinemiahemic and lymphatic diseasesSecondary HypogammaglobulinemiaInternal MedicinemedicineHumansAgedRetrospective StudiesAdult patientsbusiness.industryRetrospective cohort studyGamma globulinmedicine.diseaseElectrophoresesImmunologyEtiologyFemalebusinessEuropean journal of internal medicine
researchProduct

The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persisten…

2005

Background:  Patients with severe persistent asthma who are inadequately controlled despite treatment according to current asthma management guidelines have a significant unmet medical need. Such patients are at high risk of serious exacerbations and asthma-related mortality. Methods:  Here, we pooled data from seven studies to determine the effect of omalizumab, an anti-immunoglobulin E (IgE) monoclonal antibody, on asthma exacerbations in patients with severe persistent asthma. Omalizumab was added to current asthma therapy and compared with placebo (in five double-blind studies) or with current asthma therapy alone (in two open-label studies). The studies included 4308 patients (2511 tre…

Emergency Medical Servicesmedicine.medical_specialtyAllergyExacerbationImmunologyOmalizumabOmalizumabAntibodies Monoclonal HumanizedImmunoglobulin EPlaceboSeverity of Illness IndexInternal medicineSeverity of illnessmedicineHumansImmunology and AllergyAnti-Asthmatic AgentsRandomized Controlled Trials as TopicAsthmabiologybusiness.industryRespiratory diseaseAntibodies MonoclonalImmunoglobulin Emedicine.diseaseAsthmaAntibodies Anti-Idiotypicrespiratory tract diseasesPhysical therapybiology.proteinbusinessmedicine.drugAllergy
researchProduct

Persistence of low back pain reporting among a cohort of employees in a metal corporation: A study with 5-, 10-, and 28-year follow-ups

2005

Low back pain (LBP) is a common symptom among adults but little is known about its persistence over time in defined populations. The aim of this study was to examine the persistence of LBP among a cohort of industrial employees studied in four successive surveys during a total of 28 years. Cross-tabulations and logistic regression was used to estimate the interdependence of LBP occurrence at the surveys. At baseline, 54% of the subjects reported local LBP and 25% LBP radiating to the lower limb(s). Persistent or recurrent LBP was common. Of those with LBP at baseline, 75, 73, and 88% reported it also at the 5-, 10- or 28-year follow-up, respectively. Of those with radiating pain, 66, 65, an…

Employmentmedicine.medical_specialtyLogistic regressionRisk AssessmentSeverity of Illness IndexLower limbPersistence (computer science)Cohort StudiesAge DistributionRecurrenceSurveys and Questionnaireshealth services administrationmedicineIndustrySex DistributionProspective cohort studyFinlandPain MeasurementReferred painbusiness.industryIncidencepathological conditions signs and symptomsOdds ratioLow back painnervous system diseasesbody regionsAnesthesiology and Pain MedicineNeurologyMetallurgyCohortPhysical therapypopulation characteristicsNeurology (clinical)medicine.symptombusinessLow Back PainFollow-Up StudiesPain
researchProduct

Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer.

2011

The aim of this study was to assess the effect of adjuvant anastrozole, alone or associated with risedronate, on BMD and bone fracture risk in women more than 70 years old with hormone receptor-positive early breast cancer (EBC). In a group of 51 elderly women (aged 76.4 ± 5.0 years) considered for adjuvant aromatase inhibitors for EBC, 24 patients with T-scores ≥ -2 and no prevalent fractures received anastrozole 1 mg/day (group A), and 27 patients with T-scores < -2, or with T-scores ≥ -2 and prevalent fractures (group B), received anastrozole (1 mg/day) plus risedronate (35 mg/week). Both groups received supplementation with 1 g calcium carbonate and 800 IU vitamin D per day. Differen…

Endocrinology Diabetes and MetabolismOsteoporosisSeverity of Illness IndexCohort StudiesEndocrinologyBone DensityOrthopedics and Sports MedicineVitamin DAromataseOsteoporosis PostmenopausalAged 80 and overBone Density Conservation AgentsbiologyAromatase InhibitorsEtidronic AcidGeneral MedicineCombined Modality Therapymedicine.anatomical_structureFemaleRisedronic Acidmedicine.drugmusculoskeletal diseasesmedicine.medical_specialtyAntineoplastic Agents HormonalUrologyAnastrozoleBreast NeoplasmsAnastrozoleCalcium CarbonateNitrilesmedicineVitamin D and neurologyHumansBone ResorptionAgedNeoplasm StagingFemoral neckTrochanterbusiness.industryBone fractureTriazolesmedicine.diseaseSurgeryEarly breast cancer Anastrozole Osteoporosis Vertebral fractures ElderlyDietary SupplementsOrthopedic surgerybiology.proteinbusinessOsteoporotic FracturesFollow-Up Studies
researchProduct

Elevated serum eotaxin levels in patients with inflammatory bowel disease.

2002

OBJECTIVE: Eotaxin is a recently characterized chemokine with potent and selective chemotactic activity for eosinophils. Previous studies indicating that eosinophils accumulate and become activated in inflammatory bowel disease (IBD) led us to hypothesize that eotaxin is potentially involved in the pathophysiology of IBD and, therefore, that eotaxin would be increased in the serum of patients with IBD. The objective of this study was to test those assumptions. METHODS: We investigated 72 patients with IBD, 35 with ulcerative colitis, and 37 with Crohn’s disease. A total of 27 patients had active and 45 inactive disease; 26 were receiving corticosteroids. Eotaxin serum levels were determined…

EotaxinAdultChemokine CCL11Adolescentmedicine.medical_treatmentInflammatory bowel diseaseSeverity of Illness IndexPathogenesisLeukocyte CountPrednisoneReference ValuesmedicineHumansAgedHepatologybusiness.industryGastroenterologyrespiratory systemEosinophilMiddle Agedmedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisdigestive system diseasesPathophysiologyEosinophilsmedicine.anatomical_structureCytokineChemokines CCImmunologyColitis Ulcerativebusinessmedicine.drugThe American journal of gastroenterology
researchProduct

Do fire severity effects on soil change in space and time in the short-term? What ash tells us

2013

n the absence of data, the impact of fire, especially wildfires, is measured analysing the fire severity. This post-fire assessment is very useful because allow to identify the degree of destruction imposed by the fire. Among the techniques used to determine fire severity, ash colour is often used, that permit identify the degree of organic matter consumption (darker ash uncompleted combustion, lighter ash completed combustion). The objective of this paper was observed if fire severity changes in space and time, according to ash colour analysis, applying an index. The ash colour analysis was carried out one and fifteen days after the fire. In this area we identified ash with four different …

Fire severity indexAsh colorFire severitytechnology industry and agriculturemacromolecular substancesAsh redistributionlcsh:Science (General)complex mixturesSpatial correlationlcsh:Q1-390
researchProduct